5.09MMarket Cap0.44P/E (TTM)
3.650High2.560Low209.90KVolume2.730Open2.640Pre Close665.02KTurnover15.72%Turnover RatioLossP/E (Static)1.57MShares23.20052wk High0.17P/B4.34MFloat Cap2.00052wk Low--Dividend TTM1.34MShs Float1390.000Historical High--Div YieldTTM41.29%Amplitude2.000Historical Low3.168Avg Price1Lot Size
Purple Biotech Stock Forum
📊⚡️📊
📊⚡️📊
📊⚡️📊
Purple Biotech Identifies Potential New Serum Biomarker for Its Lead Oncology Therapeutic Candidate Cm24: Associated With 79% Reduction in Risk of Death!
Phase 2 Study of Cm24 in Pancreatic Cancer Expected Q4 2024 Results
Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR
Symposium on Molecular Targets and Cancer Therapeutics
CAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arms also seen in non-small cell lung cancer patient-derived explants
Lead tribody IM1240 data demonstrated...
No comment yet